Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market - GBI Research Reports

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market - GBI Research Reports
Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market
Published Apr 11, 2011
141 pages — Published Apr 11, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market, which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented.

Scope

The report covers -
- Data and analysis on the sleep disorders therapeutics market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the sleep disorders therapeutics market from 2002 to 2010, with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- Key drivers and restraints that have had a significant impact on the market.
- The competitive landscape of the global sleep disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Sanofi-aventis, King pharmaceuticals, questcor pharmaceuticals, Novartis, GlaxoSmithKline, plc, Pfizer and Boehringer Ingelheim
- Key M&A activities and Licensing Agreements that took place in 2008 and 2010 in the sleep disorders therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

  
Source:
Document ID
GBIHC095MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents38
  List of Tables63
  List of Figures92
Sleep Disorders Market: Introduction112
  GBI Research Report Guidance121
Sleep Disorders Market to 2017: Market Overview1310
  Introduction131
  Revenue Forecasts for the Sleep Disorder Therapeutics Market141
    Revenue141
    Annual Cost of Treatment (ACT)152
    Treatment Usage Patterns172
      Diseased Population191
      Treatment Seeking Population201
      Diagnosis Population211
      Prescription Population221
Sleep Disorders Market to 2017: Geographical Landscape2328
  Revenue Analysis by Geography232
  The US251
    Revenue251
    Annual Cost of Treatment262
    Treatment Usage Patterns282
      Diseased Population301
      Treatment Seeking Population312
      Diagnosis Population331
      Prescription Population341
  Top Five Countries of Europe351
    Revenue351
    Annual Cost of Treatment361
    Treatment Usage Patterns372
      Diseased Population391
      Treatment Seeking Population401
      Diagnosis Population411
      Prescription Population421
  Japan431
    Revenue431
    Annual Cost of Treatment441
    Treatment Usage Patterns452
      Diseased Population471
      Treatment Seeking Population481
      Diagnosis Population491
      Prescription Population501
Sleep Disorders Market: Therapeutic Landscape5141
  Insomnia Therapeutics Market511
    Introduction511
    Revenue521
    Annual Cost of Treatment531
    Treatment Usage Patterns542
      Diseased Population561
      Treatment Seeking Population571
      Diagnosis Population581
      Prescription Population591
    Drivers and Barriers for the Insomnia Therapeutics Market601
      Drivers for the Insomnia Therapeutics Market601
      Barriers for the Insomnia Therapeutics Market611
  Restless Leg Syndrome Therapeutics Market611
    Introduction611
    Revenue621
    Annual Cost of Treatment631
    Treatment Usage Patterns642
      Diseased Population661
      Treatment Seeking Population671
      Diagnosis Population681
      Prescription Population691
    Drivers and Barriers for the Restless Leg Syndrome Therapeutics Market701
      Drivers for the Restless Leg Syndrome Therapeutics Market701
      Barriers for the Restless Leg Syndrome Therapeutics Market711
  Narcolepsy Therapeutics Market711
    Introduction711
    Revenue721
    Annual Cost of Treatment731
    Treatment Usage Patterns742
      Diseased Population761
      Treatment Seeking Population771
      Diagnosis Population781
      Prescription Population791
    Drivers and Barriers for the Narcolepsy Therapeutics Market801
      Drivers for the Narcolepsy Therapeutics Market801
      Barriers for the Narcolepsy Therapeutics Market811
  Sleep Apnea Therapeutics Market811
    Introduction811
    Revenue821
    Annual Cost of Treatment831
    Treatment Usage Patterns842
      Diseased Population861
      Treatment Seeking Population871
      Diagnosed Population881
      Prescription Population891
    Drivers and Barriers for the Sleep Apnea Therapeutics Market901
      Drivers for the Sleep Apnea Therapeutics Market901
      Barriers for the Sleep Apnea Therapeutics Market911
Sleep Disorders Market to 2017: Pipeline Analysis9212
  Introduction921
  Research and Development Pipeline Sleep Disorders931
  Insomnia Pipeline Analysis931
    Introduction931
    Insomnia Therapeutics Market Pipeline Assessment by Clinical Phase of Development941
    Filed Molecules951
    Phase III951
    Phase II961
    Phase I971
    Preclinical Phase971
    Discovery Phase971
  Restless Leg Syndrome Therapeutics Market: Pipeline Analysis981
    Introduction981
    Narcolepsy Therapeutics Market Pipeline Assessment by Clinical Phase of Development991
  Narcolepsy Therapeutics Market Pipeline Analysis1001
    Introduction1001
    Narcolepsy Therapeutics Market Pipeline Assessment by Clinical Phase of Development1011
  Sleep Apnea Therapeutics Market Pipeline Analysis1021
    Introduction1021
    Sleep Apnea Therapeutics Market Pipeline Assessment by Clinical Phase of Development1031
Sleep Disorder Market to 2016: Competitive Landscape10423
  Overview1041
  Competitive Profiling1041
    Sanofi-Aventis1041
      Company Overview1041
      Marketed Products1043
    King Pharmaceuticals, Inc.1071
      Company Overview1071
      Marketed Products1071
    Questcor Pharmaceuticals, Inc.1081
      Company Overview1081
      Marketed Products1081
    Novartis1091
      Company Overview1091
      Marketed Products1092
    GlaxoSmithKline plc1111
      Company Overview1111
      Marketed Products1112
    Pfizer1131
      Company Overview1131
      Marketed Products1132
    Boehringer Ingelheim1151
      Company Overview1151
      Marketed Products1154
    Cephalon Pharmaceuticals1191
      Company Overview1191
      Marketed Products1192
    Schwarz Pharma1211
      Company Overview1211
      Marketed Products1214
    Mylan Pharma1251
      Company Overview1251
      Marketed Products1252
Sleep Disorders Market to 2017: M&A Landscape1279
  Sleep Disorders Market1271
    Overview: Deals by Type1271
    Deals by Year1281
  Mergers and Acquisitions1281
    Overview1281
    Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo1281
    Eli Lilly Acquires Hypnion1291
    Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical1291
    Sciele Pharma Acquires Alliant Pharmaceuticals1301
    Jazz Pharmaceuticals Acquires Orphan Medical1301
    Paul Royalty Acquires US Royalty Rights of Estorra from Aventis1302
  Licensing Agreements1321
    GlaxoSmithKline (GSK) and Actelion Pharmaceuticals1321
    Purdue Pharma Enters into License Agreement with Transcept Pharmaceuticals1321
    Neurocrine Biosciences Enters into Licensing Agreement with Dainippon Sumitomo Pharma1331
    Eli Lilly Enters into Licensing Agreement with Merck1331
    ECR Pharmaceuticals Enters into License Agreement with NovaDel Pharma1331
    Vanda Enters into Licensing Agreement with Bristol-Myers Squibb1341
  Co-Development Strategies1351
Sleep Disorders Market: Appendix1366
  Market Definition1361
  Abbreviations1361
  Research Methodology1374
    Coverage1371
    Secondary Research1371
    Forecasting1381
      Epidemiology-based Forecasting1382
    Primary Research1401
    Expert Panels1401
  Contact Us1401
  Disclaimer1411
  Sources1411

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market" Apr 11, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Sleep-Disorders-Market-to-2017-Generic-Substitution-Coupled-With-a-Weak-Pipeline-Will-Negatively-Impact-the-Market-2115-202>
  
APA:
GBI Research Reports. (2011). Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market Apr 11, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Sleep-Disorders-Market-to-2017-Generic-Substitution-Coupled-With-a-Weak-Pipeline-Will-Negatively-Impact-the-Market-2115-202>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.